Shandong Xinhua Pharmaceutical Company Limited operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shandong Xinhua Pharmaceutical Company Limited with three other
companies in this sector in China:
Apeloa Pharmaceutical Co Ltd
sales of 4.77 billion Chinese Renmimbi [US$692.63 million]
of which 100%
was Health Care & Pharmaceutical),
China Resources Double-Crane Pharmaceutical Company Limited
(5.49 billion Chinese Renmimbi [US$797.50 million]
of which 62%
was Non- transfusion), and
ChangChun High New Technology Industries
(2.87 billion Chinese Renmimbi [US$417.29 million]
of which 81%
During the year ended December of 2016, sales at
Shandong Xinhua Pharmaceutical Company Limited were 4.01 billion Chinese Renmimbi (US$582.96 million).
increase of 11.6%
versus 2015, when the company's sales were 3.60 billion Chinese Renmimbi.
This was the fifth consecutive year of sales increases at Shandong Xinhua Pharmaceutical Company Limited
(and since 2011, sales have increased a total of 38%).
Sales of Chemical Raw Medicine saw an increase
19.8% in 2016, from
1.48 billion Chinese Renmimbi to 1.77 billion Chinese Renmimbi.